Ulocuplumab, also known as BMS-936564 or MDX1338, is a fully human IgG4 monoclonal antibody targeting CXCR4. This antibody plays a critical role in modulating tumor microenvironment interactions by inducing apoptosis and inhibiting CXCL12-mediated activation and migration of CXCR4 in chronic lymphocytic leukemia (CLL) cells. Demonstrating significant antitumor efficacy, Ulocuplumab has shown activity against established tumors in various xenograft models, including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma. This antibody is pivotal for research focused on the molecular pathways of cancer cell migration and survival, offering potential therapeutic insights into multiple hematologic malignancies.
Ulocuplumab, also known as BMS-936564 or MDX1338, is a fully human IgG4 monoclonal antibody targeting CXCR4. This antibody plays a critical role in modulating tumor microenvironment interactions by inducing apoptosis and inhibiting CXCL12-mediated activation and migration of CXCR4 in chronic lymphocytic leukemia (CLL) cells. Demonstrating significant antitumor efficacy, Ulocuplumab has shown activity against established tumors in various xenograft models, including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma. This antibody is pivotal for research focused on the molecular pathways of cancer cell migration and survival, offering potential therapeutic insights into multiple hematologic malignancies.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
